Lenalidomide Teva

Lenalidomide, the active ingredient in Lenalidomide Teva, is an immunomodulatory drug presented as an oral tablet for oral use. It belongs to the class of immunomodulatory agents and is marketed for oral administration in the European Union. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide through regulated distribution channels and dedicated quality‑assurance processes.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone‑marrow clones. - Multiple myeloma: improves progression‑free survival and overall response rates. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle cell lymphoma: contributes to disease control in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause bleeding. - Anemia: decreased red blood cells leading to weakness. - Constipation: difficulty passing stools. - Rash: mild skin irritation or redness.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound immune suppression requiring medical intervention. - Infections: opportunistic or severe bacterial, viral, or fungal infections. - Secondary primary malignancies: emergence of new cancers. - Hypersensitivity reactions: severe allergic responses including anaphylaxis. - Liver enzyme elevation: potential hepatic injury.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor laboratory parameters. - Dose adjustment: required in renal impairment based on creatinine clearance. - Pregnancy: contraindicated; teratogenic risk requires effective contraception. - Blood monitoring: regular CBC to detect cytopenias. - Thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. - Infection risk: monitor for signs of infection and treat promptly. - Store at ambient temperature: keep below 25 °C, in original container, protect from moisture and light.

Lenalidomide can interact with several drug classes, necessitating careful review of concomitant medications.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure (e.g., rifampin). - Anticoagulants: increased risk of bleeding when combined with lenalidomide. - Live vaccines: should be avoided due to immunosuppression.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors: may increase plasma levels (e.g., verapamil). - Other immunomodulatory agents: additive myelosuppression (e.g., thalidomide). - Renal toxic drugs: monitor renal function when co‑administered (e.g., NSAIDs).